{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-23-000087","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.745825+00:00","generated_at":"2026-06-08T17:03:01.261058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maravai Q3 revenue down 65% to $66.9M, net loss of $15.1M; cuts ~100 jobs to save $30M annually","bullets":["Q3 revenue $66.9M (-65% YoY); net loss $15.1M vs net income $99.7M a year ago.","Nucleic Acid Production revenue $51.2M (-71% YoY); COVID-19 CleanCap demand fell $111.6M from prior year.","Cost realignment targets $30M annual savings, workforce reduction of ~15% (~100 employees) with $5M one-time severance.","Full-year 2023 guidance lowered to revenue $275-285M; Adjusted EBITDA margin 18% in Q3.","Partnerships with Thermo Fisher, Intellia, Elixirgen, Precision BioSciences for mRNA cap analogs."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-23-000087","json":"https://secwatch.observer/filing/0001823239-23-000087.json","markdown":"https://secwatch.observer/filing/0001823239-23-000087.md","text":"https://secwatch.observer/filing/0001823239-23-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/0001823239-23-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/mrvi-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:03:01.261058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe72e9e3308e376a7b39794aa4abcec4d4dd904a","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported the third quarter ended September 30, 2023 results: revenue $66.9 million, net income Net loss of $(15.1) million. Guidance reaffirmed.","evidence_excerpt":"reported financial results for the third quarter ended September 30, 2023, together with other business updates. Recent highlights include: Financial: • Quarterly revenue of $66.9 million, Net loss of $(15.1) million, and Adjusted EBITDA margin of 18%; and • Updated financial guidance for the full year 2023 to a revenue range of $275.0 million to $285.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/0001823239-23-000087-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$66.9 million"},{"label":"Net income","value":"Net loss of $(15.1) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}